Clinical Trials
405 trialsGEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Sun Pharma Advanced Research Company Limited
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
BHARAT-1
Aurigene Discovery Technologies Limited
VIJAY-1
Aurigene Discovery Technologies Limited
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Changchun GeneScience Pharmaceutical Co., Ltd.
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Takeda
PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia
medac GmbH
LAUREL
Inmune Bio, Inc.
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
Nerviano Medical Sciences
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
ZUMA-25
Gilead Sciences
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Hutchmed
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Servier
topMIND
Incyte Corporation
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Hutchmed
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
AvenCell Therapeutics, Inc.
STIMULUS-AML1
Novartis
STIMULUS-MDS2
Novartis
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Astellas Pharma Inc
Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
JW Pharmaceutical
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sanofi
A Phase I Study of BR108 in Hematological Malignancies
BioRay Pharmaceutical Co., Ltd.
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
ARTEMIS
Marker Therapeutics, Inc.
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
Novartis
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Novartis
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
Novartis
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Novartis
VIALE-T
AbbVie
ACHIEVE
TC Biopharm
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Schrödinger, Inc.
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
Sanofi
ISAKIDS
Sanofi
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Celgene
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
Sutro Biopharma, Inc.
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
Sanofi
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Vor Biopharma
A Long-term Follow-up Study of Patients Who Received VOR33
Vor Biopharma
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
Vor Biopharma
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Affimed GmbH